Key terms

About VERV

Verve Therapeutics, Inc. is a genetic medicines company, which engages in the development of approach to the care of cardiovascular diseases. The company was founded by Burt A. Adelman, Keith J. Joung, Sekar Kathiresan, Kiran Musunuru, Anthony Philippakis, Issi Rozen, and Barry Ticho in 2018 and is headquartered in Boston, MA.

Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
     
52-week range
     
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date

Key terms

Smart score

Latest VERV news

Apr 08 6:25am ET Buy Rating on Verve Therapeutics: Promising Gene Editing Prospects and Anticipated Recovery by TipRanks Apr 08 6:23am ET Verve Therapeutics initiated with a Buy at H.C. Wainwright by TipRanks Apr 03 7:10am ET Wall Street Analysts Are Bullish on Top Healthcare Picks by TipRanks Apr 03 7:03am ET Verve Therapeutics price target lowered to $40 from $56 at Stifel by TipRanks Apr 02 7:14pm ET Citi sees limited readthrough for Beam Therapeutics from VERVE-101 trial pause by TipRanks Apr 02 6:25pm ET Buy Rating Affirmed for Verve Therapeutics with Strategic Focus on Promising VERVE-102 Program by TipRanks Apr 02 12:59pm ET RBC remains buyer of Verve Therapeutics after enrollment pause by TipRanks Apr 02 8:42am ET Verve Therapeutics (NASDAQ:VERV) Plunges on Trial Halt by TipRanks Apr 02 8:00am ET Verve Therapeutics down 33% at $8.50 after pausing Heart-1 trial of VERVE-101 by TipRanks Apr 02 7:12am ET Verve Therapeutics pauses enrollment in Heart-1 trial of VERVE-101 by TipRanks Feb 28 3:25pm ET Buy Rating Affirmed for Verve Therapeutics Amidst Promising Clinical Studies and Strategic Advancements by TipRanks Feb 28 7:17am ET Verve Therapeutics price target lowered to $30 from $32 at Canaccord by TipRanks Feb 28 7:16am ET RBC Capital Sticks to Their Buy Rating for Verve Therapeutics (VERV) by TipRanks Jan 10 7:05am ET Verve Therapeutics: A Strong Buy on Clinical and Operational Progress by TipRanks
Apr 13 8:00pm ET INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Verve Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm by Accesswire Apr 13 6:00am ET INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Verve Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm by Accesswire Apr 12 4:30am ET IMPORTANT INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Verve Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm by Accesswire Apr 09 3:00am ET INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Verve Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm by Accesswire Apr 08 12:45pm ET INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Verve Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm by Accesswire

VERV Financials

1-year income & revenue

Key terms

VERV Forecasts

analyst rating

  • buy
  • hold
  • sell

We're sorry, but this
information is
temporarily unavailable.

1-year stock price forecast

VERV Competitors

$ Market cap P/E ratio $ Price 1d change 52-week range

Key terms

Latest investing news

In this photo illustration, Republican presidential candidate former President Donald Trump's social media platform Truth Social is shown on a cell phone on March 25, 2024 in Chicago, Illinois.
Scott Olson/Getty Images
Trump’s stock tumbles again after Truth Social announces it’s getting into streaming
Tim Wren, chief commercial officer for BSI Group, right, presents Kristalina Georgieva, chief executive officer of the World Bank Group, second right, with ISO 20121 certification for sustainable event management at an event during the spring meetings of the International Monetary Fund (IMF) and World Bank in Washington, DC, US, on Monday, April 15, 2024. The IMF and World Bank spring meetings in Washington are expected to draw thousands of delegates, observers and journalists from the fund's 190 member countries. Photographer: Samuel Corum/Bloomberg via Getty Images
Samuel Corum/Bloomberg/Getty Images
Geopolitical strife is roiling Wall Street. Here’s what investors are watching
Donald Trump might no longer own a majority of TMTG after a new public share offering.
Joe Raedle/Getty Images
Trump stock tanks after announcing massive share sale
1040 US Individual Income Tax Return Form
Nora Carol Photography/Moment RF/Getty Images
Three ways investors can minimize their tax payments